Fig. 3

Prognostic impact of MMs in MUC16 and its validation in TCGA. The frequency of SM and MMs in MUC16 was 17% and 3% in our study and 17% and 5% in TCGA. a Patient RFS was significantly worse in the group with MUC16 MMs than in the group with MUC16 SM (P = 0.022), although there was no significant difference between the group with MUC16 SM and the group with wild-type MUC16 in our cohort (P = 0.324, log-rank test). b In TCGA data sets, no significant differences in HCC-specific survival were observed between the group with MUC16 SM and the group with wild-type MUC16 (P = 0.616). Patient HCC-specific survival was significantly worse in the group with MUC16 MMs than in the group with MUC16 SM (P = 0.043) and in the group with wild-type MUC16 (P = 0.013)